Emerging T Cell Therapy Company NexImmune Receives First IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome October 31, 2019 07:30 ET | Source: NexImmune, Inc. IND clearance enables [….]
Emerging T Cell Therapy Company NexImmune Receives First IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome
